241 related articles for article (PubMed ID: 26584326)
1. Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder.
Freeman MP; Fava M; Gommoll C; Chen C; Greenberg WM; Ruth A
Int Clin Psychopharmacol; 2016 Mar; 31(2):100-9. PubMed ID: 26584326
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of levomilnacipran ER across symptoms of major depressive disorder: a post hoc analysis of 5 randomized, double-blind, placebo-controlled trials.
McIntyre RS; Gommoll C; Chen C; Ruth A
CNS Spectr; 2016 Oct; 21(5):385-392. PubMed ID: 27292817
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study.
Montgomery SA; Mansuy L; Ruth AC; Li D; Gommoll C
Int Clin Psychopharmacol; 2014 Jan; 29(1):26-35. PubMed ID: 24172160
[TBL] [Abstract][Full Text] [Related]
4. Effects of levomilnacipran ER on noradrenergic symptoms, anxiety symptoms, and functional impairment in adults with major depressive disorder: Post hoc analysis of 5 clinical trials.
Blier P; Gommoll C; Chen C; Kramer K
J Affect Disord; 2017 Mar; 210():273-279. PubMed ID: 28068615
[TBL] [Abstract][Full Text] [Related]
5. The effects of levomilnacipran ER in adult patients with first-episode, highly recurrent, or chronic MDD.
Kornstein SG; Gommoll C; Chen C; Kramer K
J Affect Disord; 2016 Mar; 193():137-43. PubMed ID: 26773906
[TBL] [Abstract][Full Text] [Related]
6. A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder.
Sambunaris A; Bose A; Gommoll CP; Chen C; Greenberg WM; Sheehan DV
J Clin Psychopharmacol; 2014 Feb; 34(1):47-56. PubMed ID: 24172209
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials.
Montgomery SA; Gommoll CP; Chen C; Greenberg WM
CNS Spectr; 2015 Apr; 20(2):148-56. PubMed ID: 24902007
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of functional health and well-being in patients receiving levomilnacipran ER for the treatment of major depressive disorder.
Blum SI; Tourkodimitris S; Ruth A
J Affect Disord; 2015 Jan; 170():230-6. PubMed ID: 25259674
[TBL] [Abstract][Full Text] [Related]
9. Effects of levomilnacipran extended-release on major depressive disorder patients with cognitive impairments: post-hoc analysis of a phase III study.
Wesnes KA; Gommoll C; Chen C; Sambunaris A; McIntyre RS; Harvey PD
Int Clin Psychopharmacol; 2017 Mar; 32(2):72-79. PubMed ID: 27861191
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.
Montgomery SA; Mansuy L; Ruth A; Bose A; Li H; Li D
J Clin Psychiatry; 2013 Apr; 74(4):363-9. PubMed ID: 23656841
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials.
Sambunaris A; Gommoll C; Chen C; Greenberg WM
Int Clin Psychopharmacol; 2014 Jul; 29(4):197-205. PubMed ID: 24667487
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study.
Asnis GM; Bose A; Gommoll CP; Chen C; Greenberg WM
J Clin Psychiatry; 2013 Mar; 74(3):242-8. PubMed ID: 23561229
[TBL] [Abstract][Full Text] [Related]
13. Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study.
Bakish D; Bose A; Gommoll C; Chen C; Nunez R; Greenberg WM; Liebowitz M; Khan A
J Psychiatry Neurosci; 2014 Jan; 39(1):40-9. PubMed ID: 24144196
[TBL] [Abstract][Full Text] [Related]
14. Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2013 Nov; 67(11):1089-104. PubMed ID: 24016209
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies.
Weisler RH; Montgomery SA; Earley WR; Szamosi J; Lazarus A
Int Clin Psychopharmacol; 2012 Jan; 27(1):27-39. PubMed ID: 22027845
[TBL] [Abstract][Full Text] [Related]
16. Effects of levomilnacipran extended-release on motivation/energy and functioning in adults with major depressive disorder.
Thase ME; Gommoll C; Chen C; Kramer K; Sambunaris A
Int Clin Psychopharmacol; 2016 Nov; 31(6):332-40. PubMed ID: 27455513
[TBL] [Abstract][Full Text] [Related]
17. Effect of desvenlafaxine 50 mg and 100 mg on energy and lassitude in patients with major depressive disorder: A pooled analysis.
Lam RW; Wajsbrot DB; Meier E; Pappadopulos E; Mackell JA; Boucher M
J Psychopharmacol; 2017 Sep; 31(9):1204-1214. PubMed ID: 28718346
[TBL] [Abstract][Full Text] [Related]
18. Levomilnacipran extended-release: a review of its use in adult patients with major depressive disorder.
Scott LJ
CNS Drugs; 2014 Nov; 28(11):1071-82. PubMed ID: 25270036
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the efficacy of vilazodone in achieving remission in patients with major depressive disorder: post-hoc analyses of a phase IV trial.
Citrome L; Gommoll CP; Tang X; Nunez R; Mathews M
Int Clin Psychopharmacol; 2015 Mar; 30(2):75-81. PubMed ID: 25396353
[TBL] [Abstract][Full Text] [Related]
20. No predictors of antidepressant patient response to milnacipran were obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale in Japanese patients with major depressive disorders.
Higuchi H; Sato K; Yoshida K; Takahashi H; Kamata M; Otani K; Yamaguchi N
Psychiatry Clin Neurosci; 2008 Apr; 62(2):197-202. PubMed ID: 18412843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]